ClinicalTrials.gg
RecruitingNCT05439083Updated Mar 8, 2024

Immunogenicity of 9-valent HPV Vaccine

A Phase 4 interventional study of 9-valent HPV vaccine in Human Papilloma Virus Infection, sponsored by Talia Sainz Costa. Recruiting at 1 site in Spain. Open to participants aged 9 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-08.

Sponsored by Talia Sainz Costa · Phase 4, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
9 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections — 10 open to participants now, 20 under way, 8 of them phase 3. Human Papillomavirus Recombinant Vaccine nonavalent · Papillomavirus Infections.

Planned enrollment
27th of 31
120 · median 700
Started
2023
the only one that year
Phase 4
10 of 31
4 open now
Primary completion
2024-09
later than 2 of 19 live
Registered
23rd of 31
by date

Among the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, this one is the 27th largest by planned enrollment, is the only one that started in 2023, is one of 10 in phase 4, reaches primary completion later than 2 of the 19 other live ones, and was the 23rd registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

10 of the 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections are open now, in 9 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About Human Papillomavirus Recombinant Vaccine nonavalent

Human Papillomavirus Recombinant Vaccine nonavalent: first FDA approval 2014 (Gardasil 9). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 9 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing Human Papillomavirus Recombinant Vaccine nonavalent in Papillomavirus Infections, or all of them as a file.
02

Study summary

Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately 90% of cervical and other HPV-related anogenital cancers, as well as 90% of genital warts. The risk of cancer is substantially increased among immunocompromised patients.

Although studies have demonstrated seroprotection among children and adolescents, boys and girls, with the 9vHPV vaccine, the immunogenicity of this vaccine has been poorly explored in immunocompromised children and adolescents (including transplant patients, and those infected with human immunodeficiency virus (HIV)). Several factors, including the immunological consequences of vertically acquired infection, immunosuppressive therapies and age, could lead to an increased risk of infection in children and adolescents who are immunocompromised. Lower immunogenicity in these populations. These children may have a poor response to vaccines and therefore require additional doses. Markers such as CD4/CD8 or torque teno virus (TTV) replication could be linked to immunogenicity and thus serve as predictors of efficacy for routine clinical practice.

03

Conditions studied

  • Human Papilloma Virus Infection
04

Who can participate

Ages eligible
9 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children or adolescents 9 to \<18 years of age
  • Willing to sign consent/assent form
  • If positive, under ART and undetectable viral load and >200/mm3 (at least 6 months)
  • If the patient has received chemotherapy or is a SOT/ recipient, referred for immunizations after adequate immune reconstitution according to routine clinical practice

Exclusion criteria

Exclusion Criteria:

  • Previous history of warts and/or anal cancer.
  • Previous immunization with any HPV vaccine.
  • Age below 9.
  • Patients who for any reason should not be included in the study according to the evaluation of the research team.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Immunosuppressed Group

    N=90 Immunosuppressed patients, consisting of HIV-infected children and adolescents, hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant (SOT) recipients and post-chemotherapy patients (PCT) under follow up at Hospital La Paz in Madrid Spain. 9-valent HPV vaccine: three-dose schedule: Months 0-2-6.

    Biological: 9-valent HPV vaccine

  • Other
    Control Group

    N=30 Healthy controls aged 9-14 9-valent HPV vaccine: two-dose schedule: Months 0-6.

    Biological: 9-valent HPV vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Seroconversion of subjects from baseline to month 7 (determined by serum anti-HPV antibody titers)

    Percentage of subjects seroconverting from baseline to month 7

    Time frame: From baseline to month 7

  2. Seroconversion of subjects from baseline to month 12 (determined by serum anti-HPV antibody titers)

    Percentage of subjects maintaining antibody titers 12 months after immunization.

    Time frame: From baseline to month 12

  3. Seroconversion of subjects from baseline to month 18 (determined by serum anti-HPV antibody titers)

    Percentage of subjects maintaining antibody titers 18 months after immunization.

    Time frame: From baseline to month 18

Secondary outcomes

  1. Ratio of geometric mean serum antibody titers (GMTs)

    GMTs from baseline to month 7

    Time frame: From baseline to month 7

  2. Delta of geometric mean serum antibody titers

    Delta of geometric mean serum antibody titers from 1 to 12 months after immunization.

    Time frame: From 1 to 12 months

  3. Percentage of subjects seroconverting from baseline to month 7

    Percentage of subjects seroconverting from baseline to month 7 in each of the study populations.

    Time frame: From baseline to month 7

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Sep 2024, 17 months after the start.

Of 28 phase 4 interventional studies under Papillomavirus Infections, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 92. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Mar 7, 2023
Primary completionEst.
Sep 1, 2024
CompletionEst.
Mar 1, 2025
Last update
Mar 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05439083
Lead sponsor
Talia Sainz Costa
Responsible party
Talia Sainz Costa (Principal Investigator, Instituto de Investigación Hospital Universitario La Paz) — Sponsor-investigator
First posted
Jun 30, 2022
Start date
Mar 7, 2023
Primary completion
Sep 1, 2024 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Mar 8, 2024

Study contacts

Talia Saínz Costa
Contact
talia.sainz@salud.madrid.org
+ 34 91 727 74 43

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion